aTYR PHARMA INC
aTYR PHARMA INC (ATYR): 6 pipeline candidates · 2 upcoming catalysts · ~15 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
15.3 months
0% dilution
Lead: Approved
6 candidates
2 upcoming, next in ~845d
1 buy · 3 sells (180d)
A transparent, data-derived signal for aTYR PHARMA INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$43.5M
Cash
$10.0M
Quarterly Burn
$12.5M
Runway
15.3 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| ATYR0101 | Preclinical |
| ATYR0750 | Preclinical |
| citric acid; magnesium oxide; sodium pico | Approved |
| citric acid; magnesium oxide; sodium pico | Approved |
| efzofitimod | Phase 3 |
| fingolimod | Approved |
Upcoming Catalysts (2)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
112
Total value held
$43.2M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 14,706,843 | $11.5M |
| federated hermes, inc. | 10,509,678 | $8.2M |
| vanguard capital management llc | 7,624,264 | $5.9M |
| blackrock, inc. | 6,443,904 | $5.0M |
| geode capital management, llc | 2,385,485 | $1.9M |
| state street corp | 1,754,399 | $1.4M |
| millennium management llc | 1,641,246 | $1.3M |
| morgan stanley | 1,225,467 | $956K |
| two sigma investments, lp | 1,144,565 | $893K |
| susquehanna international group, llp | 1,132,344 | $883K |
Showing top 10 of 112 institutional holders of aTYR PHARMA INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in aTYR PHARMA INC's pipeline?
aTYR PHARMA INC (ATYR) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is aTYR PHARMA INC's lead drug candidate?
aTYR PHARMA INC's most advanced tracked candidate is ATYR0101 (Preclinical) for Fibrotic diseases (pulmonary fibrosis, SSc, liver fibrosis and kidney fibrosis).
What is aTYR PHARMA INC's next catalyst?
aTYR PHARMA INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: PREPOPIK" — expected October 10, 2028.
What is aTYR PHARMA INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, aTYR PHARMA INC has approximately 15.3 months of cash runway.
What is aTYR PHARMA INC's market capitalization?
aTYR PHARMA INC's market capitalization is approximately $43.5M.
Get the full picture on aTYR PHARMA INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.